Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced Metastatic NSCLC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05631249
What this trial is testing

Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

Who this might be right for
KRAS P.G12CNon Small Cell Lung Cancer
Gustave Roussy, Cancer Campus, Grand Paris 40
Post-approval studies (Phase 4)Study completedNCT02208843
What this trial is testing

Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 60
Large-scale testing (Phase 3)Not Yet RecruitingNCT06380348
What this trial is testing

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Who this might be right for
Local Advanced or Metastatic NSCLC
Shanghai JMT-Bio Inc. 398
Large-scale testing (Phase 3)WithdrawnNCT05791097
What this trial is testing

Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT01633645
What this trial is testing

Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerMetastatic
University Hospital of Crete 53
Testing effectiveness (Phase 2)Looking for participantsNCT07538804
What this trial is testing

Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 294
Large-scale testing (Phase 3)UnknownNCT03792074
What this trial is testing

To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer

Who this might be right for
Non-squamous Cell Non-small Cell Lung Cancer
Sinocelltech Ltd. 560
Early research (Phase 1)Looking for participantsNCT06612840
What this trial is testing

GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors

Who this might be right for
Non-small Cell Lung CancerSolid Tumor
Sichuan Baili Pharmaceutical Co., Ltd. 20
Testing effectiveness (Phase 2)Ended earlyNCT05070247
What this trial is testing

TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Pancreatic CancerHepatocellular CancerMesothelioma+7 more
Takeda 61
Large-scale testing (Phase 3)Study completedNCT01853826
What this trial is testing

An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 481
Testing effectiveness (Phase 2)Looking for participantsNCT06667076
What this trial is testing

Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 480
Testing effectiveness (Phase 2)Study completedNCT01530334
What this trial is testing

Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment

Who this might be right for
Lung Cancer
AstraZeneca 61
Early research (Phase 1)Ended earlyNCT05573035
What this trial is testing

Investigate LYL845 in Adults With Solid Tumors

Who this might be right for
MelanomaNon-small Cell Lung CancerColorectal Cancer
Lyell Immunopharma, Inc. 39
Testing effectiveness (Phase 2)Study completedNCT00191490
What this trial is testing

Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company 162
Not applicableStudy completedNCT03017885
What this trial is testing

Post Marketing Surveillance of Nintedanib in Indian Patients With Non-small Cell Lung Cancer (NSCLC) After First-line Therapy

Who this might be right for
Non-small Cell Lung Cancer
Boehringer Ingelheim 28
Testing effectiveness (Phase 2)Looking for participantsNCT06475300
What this trial is testing

BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Who this might be right for
Non-small Cell Lung CancerNasopharyngeal CarcinomaSolid Tumor
Sichuan Baili Pharmaceutical Co., Ltd. 570
Early research (Phase 1)Active Not RecruitingNCT03993873
What this trial is testing

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorsMET Gene Alterations
Turning Point Therapeutics, Inc. 95
Testing effectiveness (Phase 2)UnknownNCT04895930
What this trial is testing

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Who this might be right for
Non-Small-Cell Lung Cancer
Shanghai Chest Hospital 40
Large-scale testing (Phase 3)Active Not RecruitingNCT05668988
What this trial is testing

DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Who this might be right for
Non-small Cell Lung Cancer
Dizal Pharmaceuticals 324
Not applicableStudy completedNCT01955681
What this trial is testing

A Retrospective, Non-interventional, Multicenter, Observational Chart Review Study to Explore the Clinical Benefits of Retreatment With TKI in the Real World.

Who this might be right for
Locally Advanced or Metastatic EGFR Mutated NSCLC.
AstraZeneca 200
Next Page